Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0000097,
umls-concept:C0005680,
umls-concept:C0009491,
umls-concept:C0013030,
umls-concept:C0026809,
umls-concept:C0030567,
umls-concept:C0030685,
umls-concept:C0391871,
umls-concept:C0439282,
umls-concept:C0441472,
umls-concept:C0599779,
umls-concept:C0680255,
umls-concept:C1283071,
umls-concept:C1519355,
umls-concept:C1522326,
umls-concept:C1963578,
umls-concept:C2587213
|
pubmed:issue |
1
|
pubmed:dateCreated |
1991-7-10
|
pubmed:abstractText |
Effects of L-DOPA (0.1-10,000 nM) on spontaneous release (Sp), evoked release (S) and tissue content (C) of dopamine (DA) were studied comparatively in superfused striatal slices from control and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mice to obtain evidence for L-DOPA-induced facilitation of S via presynaptic beta-adrenoceptors. In control slices, isoproterenol-induced concentration-dependent increases in S were propranolol-sensitive. L-DOPA at 0.1-3 nM tended to increase the S of DA with a concomitant tendency of increases in Sp. L-DOPA at 10-1 x 10(4) nM concentration-dependently increased Sp. L-DOPA at 1-10 microM tended to increase S and 10 microM increased C. In slices from MPTP-treated mice, the absolute amounts of Sp, S and C decreased by half compared to those in control slices. L-DOPA at 3 nM facilitated S without increasing Sp. This facilitation was antagonized by propranolol at 3 nM. L-DOPA at 30 nM decreased S from the peak facilitation, which contrasted with no effect in the control slices. However, 10-100 nM L-DOPA increased Sp more markedly than that in the control slices. L-DOPA at 100 nM increased S and C, which contrasted with no effect in the control slices. In conclusion, nanomolar L-DOPA facilitates the S of DA via presynaptic beta-adrenoceptors at concentrations lower than those required to induce conversion to DA even in striatal slices from the MPTP-treated mice model for Parkinson's disease.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0021-5198
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
55
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
93-100
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1645816-1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine,
pubmed-meshheading:1645816-Animals,
pubmed-meshheading:1645816-Corpus Striatum,
pubmed-meshheading:1645816-Disease Models, Animal,
pubmed-meshheading:1645816-Dopamine,
pubmed-meshheading:1645816-Isoproterenol,
pubmed-meshheading:1645816-Levodopa,
pubmed-meshheading:1645816-Mice,
pubmed-meshheading:1645816-Mice, Inbred C57BL,
pubmed-meshheading:1645816-Parkinson Disease, Secondary,
pubmed-meshheading:1645816-Receptors, Adrenergic, beta,
pubmed-meshheading:1645816-Synapses
|
pubmed:year |
1991
|
pubmed:articleTitle |
Nanomolar L-dopa facilitates release of dopamine via presynaptic beta-adrenoceptors: comparative studies on the actions in striatal slices from control and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mice, an animal model for Parkinson's disease.
|
pubmed:affiliation |
Department of Pharmacology, Yokohama City University School of Medicine, Japan.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
In Vitro,
Research Support, Non-U.S. Gov't
|